Champions Oncology (NASDAQ:CSBR ) Q4 2025 Earnings Call July 23, 2025 4:30 PM ET Company Participants David Barry Miller - Chief Financial Officer Ronnie Morris - CEO & Director Conference Call Participants Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Greetings. Welcome to the Champions Oncology Fourth Quarter Fiscal Year 2025 Earnings Call.
Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR's unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales.
Champions Oncology, Inc. (NASDAQ:CSBR ) Q3 2025 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Ronnie Morris - CEO David Miller - CFO Conference Call Participants Maj Soueidan - GeoInvesting George Marema - Pareto Ventures Operator Greetings. Welcome to the Champions Oncology Third Quarter Fiscal Year 2025 Earnings Call [Operator Instructions].
| Biotechnology Industry | Healthcare Sector | Robert Brainin CEO | XFRA Exchange | US15870P3073 ISIN |
| US Country | 210 Employees | - Last Dividend | 12 Aug 2015 Last Split | 10 Jan 2003 IPO Date |
Champions Oncology, Inc. is a groundbreaking research company in the United States that focuses on providing transformative technology solutions for drug discovery and development. The company stands out for its Tumorgraft Technology Platform, which pioneers in offering personalized cancer care by implanting human tumors in immune-deficient mice. This methodology not just positions Champions Oncology at the forefront of cancer research but also reflects its commitment towards innovating for more tailored and effective cancer treatments. Originally operating under the name Champions Biotechnology, Inc., the company underwent a name change to Champions Oncology, Inc. in April 2011, marking a pivotal transformation in its operational ethos and focus. Founded in 1985 and currently headquartered in Hackensack, New Jersey, Champions Oncology, Inc. employs a diverse marketing strategy that encompasses internet promotion, word-of-mouth endorsements, and a dedicated sales force, aiming to broaden its reach to patients and medical professionals alike.
This innovative platform lies at the heart of Champions Oncology's initiatives, enabling personalized cancer treatment methodologies. It involves the implantation of human tumors into immune-deficient mice, which then serve as models for developing and testing cancer treatments. This process is designed to identify the most effective treatment paths tailored to individual patient profiles, thus improving the precision and efficacy of cancer care.
Champions Oncology extends its technological prowess to assist pharmaceutical and biotechnology companies in their drug development processes. Through its Translational Oncology Solutions, the company leverages its Tumorgraft Technology Platform to facilitate the preclinical evaluation of new drugs, offering valuable insights into their efficacy and potential applications in oncology. This service fosters collaboration between Champions Oncology and drug developers, accelerating the journey from discovery to marketplace.
As a testament to its commitment to harnessing the power of technology in cancer research, Champions Oncology offers Lumin Bioinformatics, a sophisticated analytic and visualization software. Designed for cancer biologists, this dynamic tool empowers users to leverage computational science in their research efforts. It facilitates the analysis and interpretation of complex biological data, enabling scientists to make informed decisions and foster advancements in the field of oncology. Lumin Bioinformatics stands out as a user-friendly yet powerful tool for modern cancer research endeavors.